George Washington University School of Medicine & Health Sciences

George Washington University Webinar to Discuss Combatting Clinician Burnout with Emergent Infections

Retrieved on: 
Friday, October 27, 2023

WASHINGTON, Oct. 27, 2023 /PRNewswire/ -- The George Washington University School of Medicine and Health Sciences (SMHS) is hosting a free webinar on November 1st to discuss the issue of clinician burnout and how it can be addressed through emergent infections. The webinar is a part of a training series for the Two in One: HIV + COVID Screening and Testing Model, a national medical education program, and will feature Leon McCrea II, MD, MPH, senior associate dean of diversity, equity and inclusion at Drexel University, and Annette Gadegbeku, MD, associate dean of community health at Drexel University College of Medicine and an associate professor in the department of family, community & preventive medicine and chief of the division of community health.

Key Points: 
  • Training series highlights solutions for HIV, PrEP/PEP and COVID-19 vaccine screenings
    WASHINGTON, Oct. 27, 2023 /PRNewswire/ -- The George Washington University School of Medicine and Health Sciences (SMHS) is hosting a free webinar on November 1st to discuss the issue of clinician burnout and how it can be addressed through emergent infections.
  • The event is entitled "Combating PCP Burnout with Emergent Infections."
  • During the webinar, attendees will learn about emergent infections that clinicians have had to become familiar with; learn how to recognize signs of clinician burnout; and list strategies to combat clinician burnout through addressing a range of emergent infections.
  • The program is actively engaged in formulating policy recommendations for adjusting clinical guidelines on COVID vaccine, HIV and PrEP/PEP screenings.

ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis

Retrieved on: 
Tuesday, October 24, 2023

During the event, ASLAN will present additional analyses of the TREK-AD patient population building on data recently published at the 32nd European Academy of Dermatology and Venereology (EADV) Congress.

Key Points: 
  • During the event, ASLAN will present additional analyses of the TREK-AD patient population building on data recently published at the 32nd European Academy of Dermatology and Venereology (EADV) Congress.
  • ASLAN will also present new insights on the AD treatment landscape based on a recently conducted survey of physicians and AD patients in the US.
  • “We are pleased to be contributing to today’s discussion that aims to spark a dialogue on the changing AD patient profile that presents in clinical studies.
  • Register here to attend the webcast or watch the replay of the event, which will be available for 180 days.

Excision BioTherapeutics Announces Presentation of Interim Clinical Data for EBT-101 in Latent HIV at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress

Retrieved on: 
Thursday, October 19, 2023

SAN FRANCISCO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, today announced that interim clinical safety and biodistribution data will be presented at the 30th European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress, which will be held from October 24-27, 2023, in Brussels, Belgium.

Key Points: 
  • SAN FRANCISCO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, today announced that interim clinical safety and biodistribution data will be presented at the 30th European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress, which will be held from October 24-27, 2023, in Brussels, Belgium.
  • Dr. Rachel Presti of Washington University School of Medicine, a principal investigator for the clinical evaluation of EBT-101, will offer the first look at interim safety and biodistribution data from the EBT-101-001 Phase 1/2 clinical trial.
  • EBT-101 is being evaluated in a first-in-human clinical study to assess its safety and efficacy in people with HIV on antiretroviral therapy.
  • The presentation details are listed below, and the full program is available on the ESGCT website .

ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis

Retrieved on: 
Wednesday, October 18, 2023

Register here to attend the webinar event on October 24, 2023 at 11:00 am ET

Key Points: 
  • Register here to attend the webinar event on October 24, 2023 at 11:00 am ET
    SAN MATEO, Calif. and SINGAPORE, Oct. 18, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it will co-host a panel discussion with a leading Clinical Research Organization (CRO), “The Changing Face of Atopic Dermatitis: How the Clinical Trial and Treatment Landscape Has Changed in the Seven Years Following Dupilumab’s Introduction”, that will feature Key Opinion Leaders (KOLs) Jonathan Silverberg, MD, PhD, MPH (The George Washington University School of Medicine and Health Sciences), and April W. Armstrong, MD, MPH (UCLA Health).
  • The webinar event will include presentations by ASLAN and the CRO followed by a panel discussion with both KOLs, on the changes in the clinical trial and treatment landscape in atopic dermatitis (AD), the impact these changes have on clinical data and new therapies, and potential solutions for optimizing AD trials.
  • ASLAN management will discuss data from the Phase 2b TREK-AD study of eblasakimab and will present new market research from surveys of AD patients and prescribers on their views of current and future therapies.
  • Register here to attend the webcast from 11:00 am – 12:00 pm ET on Tuesday, October 24, 2023, or watch the replay of the event.

Iterative Health Presents Award-Winning Research on the Benefits of Gastroenterological Technology at the American College of Gastroenterology Annual Scientific Meeting

Retrieved on: 
Monday, October 23, 2023

Iterative Health , a pioneer in precision-medicine technologies for gastroenterology, announced today the results of new research unveiled at the American College of Gastroenterology (ACG) Annual Scientific Meeting.

Key Points: 
  • Iterative Health , a pioneer in precision-medicine technologies for gastroenterology, announced today the results of new research unveiled at the American College of Gastroenterology (ACG) Annual Scientific Meeting.
  • This research represents strides toward enhancing the detection of precursor adenomas and streamlining clinical trial recruitment processes in gastroenterology, ultimately bringing us closer to a future of advancing patient care in the field.
  • The publications include:
    Authors: William Holderman, MD; Parth Jain; Mitchell Reddan, MS; Haig Soghigian, MBA; Christopher Fourment, MD.
  • To learn more about Iterative Health, please visit iterative.health .

Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

Retrieved on: 
Saturday, October 14, 2023

NOVATO, Calif., VANCOUVER, British Columbia and LONDON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) today announced interim data from the Phase 2 portion of the Phase 2/3 Orbit study demonstrating that treatment with setrusumab (UX143) significantly reduced incidence of fractures in patients with OI with at least 6 months of follow-up and continues to demonstrate ongoing and meaningful improvements in lumbar spine bone mineral density (BMD). The data were presented in a late-breaker presentation at the American Society for Bone and Mineral Research 2023 Annual Meeting (ASBMR).

Key Points: 
  • In the 2 years prior to treatment with setrusumab all patients experienced at least 1 fracture.
  • Following initiation of treatment with setrusumab, 20 patients experienced no radiographic-confirmed fractures, and 4 patients experienced 7 radiographic-confirmed fractures in 5 separate events.
  • The global, seamless Phase 2/3 Orbit study is evaluating the effect of setrusumab on clinical fracture rate in patients aged 5 to
  • All patients will transition to an extension period and receive open-label setrusumab after the Phase 3 primary analysis is complete.

George Washington University Webinar to Share Tips for Improving Patient Communication Through Language and Literacy

Retrieved on: 
Wednesday, October 11, 2023

WASHINGTON, Oct. 11, 2023 /PRNewswire/ -- The George Washington University School of Medicine and Health Sciences (SMHS) is hosting a free webinar on October 25 to discuss culturally responsive communication in the primary care setting. The webinar is a part of a training series for the Two in One: HIV + COVID Screening and Testing Model, a national medical education program, and will feature Joaquín Carcaño, director of community organizing at the Latino Commission on AIDS.

Key Points: 
  • "We are excited to hear from Joaquín Carcaño and learn about another dimension of culturally responsive communication in the primary care setting."
  • The event is entitled "Culturally Responsive Communication, Part III: Language and Literacy Access."
  • During the webinar, attendees will continue to learn about how culturally responsive communication can support and uplift racial, ethnic, sexual and gender minoritized patients.
  • Additionally, the webinar will provide primary care practitioners with the tools to navigate the language and literacy needs of their patients.

Dr. Laura M. Tiedemann, Esteemed Oculoplastics Surgeon, Joins OCLI Vision's Growing Team

Retrieved on: 
Friday, September 29, 2023

GARDEN CITY, N.Y., Sept. 29, 2023 /PRNewswire-PRWeb/ -- OCLI Vision is proud to welcome Laura M. Tiedemann, MD, to their esteemed team of ophthalmologists. Dr. Tiedemann is a highly skilled and compassionate oculoplastics surgeon who brings her extensive expertise and dedication to patient care to the OCLI family. "As a New Jersey native, I am excited to join OCLI Vision and return to the tri-state area," Dr. Tiedemann shared. "Providing exceptional care to my patients has always been a passion of mine, and I am eager to make a meaningful impact on the eye health of my community."

Key Points: 
  • Esteemed oculoplastics surgeon Dr. Laura M. Tiedemann has joined OCLI Vision, specializing in minimally invasive cosmetic and reconstructive eye treatments.
  • GARDEN CITY, N.Y., Sept. 29, 2023 /PRNewswire-PRWeb/ -- OCLI Vision is proud to welcome Laura M. Tiedemann, MD, to their esteemed team of ophthalmologists.
  • Dr. Tiedemann is a highly skilled and compassionate oculoplastics surgeon who brings her extensive expertise and dedication to patient care to the OCLI family.
  • "As a New Jersey native, I am excited to join OCLI Vision and return to the tri-state area," Dr. Tiedemann shared.

Honor the Gift disputes CMS' claim that there is no change in Medicare coverage of blood tests for monitoring rejection in transplant patients

Retrieved on: 
Wednesday, September 27, 2023

WASHINGTON, Sept. 27, 2023 /PRNewswire/ -- Honor the Gift, a coalition representing organ transplant patients across the nation, along with other allied leaders across the transplant field, respond to the Centers for Medicare & Medicaid Services' (CMS) press release stating that "neither CMS nor the Medicare Administrative Contractors (MACs) have made changes that affect patients' ability to have blood tests used to monitor for organ transplantation rejection covered when ordered by their physicians in medically appropriate circumstances."  

Key Points: 
  • The Honor the Gift coalition finds this statement inaccurate and contradicted by patients and physicians nationwide.
  • The changes announced on March 2, 2023, have alarmed transplant patients and clinicians across the nation, followed by an apparent decline in physician ordering of these vital blood tests1.
  • The Honor the Gift coalition and allies dispute this assertion – this is not a "clarification" but a change in coverage policy.
  • The concerns raised by patients, clinicians, and Congress emphasize the need for continued dialogue to restore longstanding Medicare coverage.

Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older

Retrieved on: 
Tuesday, September 12, 2023

In clinical studies, once-daily roflumilast cream provided rapid clearance of the disease.

Key Points: 
  • In clinical studies, once-daily roflumilast cream provided rapid clearance of the disease.
  • Roflumilast cream is uniquely formulated with HydroARQ Technology™ as a non-greasy emollient cream that absorbs quickly and does not disrupt the skin barrier.
  • “Topical roflumilast cream was intentionally formulated with the atopic dermatitis patient in mind, and does not contain excipients that disrupt skin-barrier integrity or are common contact allergens.
  • I would like to thank the team at Arcutis for their incredible hard work and dedication,” added Watanabe.